


RealRate

PHARMACEUTICAL 2018

## Amphastar Pharmaceuticals Inc. Rank 32 of 349









PHARMACEUTICAL 2018





Amphastar Pharmaceuticals Inc. Rank 32 of 349

The relative strengths and weaknesses of Amphastar Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Amphastar Pharmaceuticals Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 367% points. The greatest weakness of Amphastar Pharmaceuticals Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 201% points.

The company's Economic Capital Ratio, given in the ranking table, is 138%, being 416% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	187,778
Cost of Goods Sold	149,380
Intangible Assets	0
Liabilities, Current	67,192
Liabilities, Non-Current	7,060
Other Assets	81,548
Other Compr. Net Income	2,596
Other Expenses	932
Other Liabilities	43,084
Other Net Income	2,518
Property and Equipment	185,339
Research and Development	43,415
Revenues	240,175
Selling, General and Administrative Expense	44,458

Output Variable	Value in 1000 USD
Assets	454,665
Liabilities	117,336
Expenses	238,185
Stockholders Equity	337,329
Net Income	4,508
Comprehensive Net Income	5,806
Economic Capital Ratio	138%

